CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

ABSTRACT:

Background

Though efforts have been made toward standardizing access to quality cancer care in Japan, there are still geographical and institutional disparities in the level of cancer care availability. We investigated the utilization of cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy (CDK4/6i+ET) as first-line (1 L) treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan.

Research design and methods

This cross-sectional survey included physicians who had treated ≥3 1 L patients with HR+/HER2- ABC in the past year.

Results

Of 41,695 physicians invited, 300 were included in the analysis. The mean percentage share of CDK4/6i+ET and ET monotherapy was 38.3% and 42.2%, resp

SUBMITTER: Nakayama T 

PROVIDER: S-EPMC11792832 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature